BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL

Clinical trials are an important part of providing new medicines to those who need them. Learn more about each of our clinical trials below.
Zelnecirnon (RPT193) for the treatment of eczema (atopic dermatitis)

RAPT Therapeutics is developing a potential treatment called zelnecirnon for eczema.

Zelnecirnon (RPT193) for the treatment of asthma

RAPT Therapeutics is developing a potential treatment called zelnecirnon for asthma.

Tivumecirnon (FLX475) FOR THE TREATMENT OF CANCER

RAPT Therapeutics is developing a potential treatment called tivumecirnon alone and/or in combination with KEYTRUDA® (pembrolizumab).

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp.

Learn more about the study for people with various types of advanced cancers